TELO Telomir Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1971532 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY51.3%
TTM EPS YoY-159.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-96.3%
ROA-91.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets5.1%
Debt / equity0.00x
Current ratio19.60x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-15.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $2.44M | $2.24M | $1.57M | $833,206 |
| SG&A expense | $8.10M | $9.64M | $600,192 | $20,941 |
| Interest expense | — | $4.34M | $1.64M | — |
| Net income | -$10.41M | -$16.53M | -$13.07M | -$854,147 |
| EPS (basic) | -0.33 | -0.56 | 0.48 | -0.03 |
| EPS (diluted) | -0.33 | -0.56 | 0.48 | -0.03 |
| Weighted avg. shares (diluted) | 31.65M | 29.54M | 27.30M | 26.83M |
| Balance sheet | ||||
| Cash & equivalents | $7.29M | $1.27M | $1,231 | $1,419 |
| Current assets | $7.34M | $1.32M | $435,225 | $48,730 |
| Total assets | $7.34M | $1.32M | $4.77M | $48,730 |
| Current liabilities | $1.43M | $680,968 | $1.34M | $986,008 |
| Total liabilities | $1.43M | $680,968 | $1.34M | $986,008 |
| Shareholders' equity | $5.91M | $643,037 | $3.44M | -$937,278 |
| Shares outstanding | 34.38M | 29.76M | 28.61M | 26.83M |
| Cash flow statement | ||||
| Operating cash flow | -$3.69M | -$5.07M | -$3.86M | -$468,661 |
| Financing cash flow | $9.71M | $6.34M | $3.86M | $470,080 |
| Stock-based compensation | $5.29M | $6.87M | — | — |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.